Introduction
IHH is the predominant Hh ligand in murine mutant Kras LAD. 207 With the disparate outcomes of genetic SHH loss ( Fig. 2c , e, f) and pharmacologic 208 blockade by 5E1 ( Fig. 3b, d -k) , we hypothesized that IHH may play a role in LAD 209 tumorigenesis as 5E1 binds both SHH and IHH. We verified that 5E1 can inhibit stromal 210 pathway activation by IHH using Shh-Light2 cells stimulated with either recombinant 211 IHH (rIHH) or rSHH ( Fig. 4a ). Of note, there was almost no induction of pathway activity 212 with recombinant DHH treatment (results are not shown). As reliable antibodies for IHH 213 IHC and immunoblots were not commercially available, we turned to RNA in situ 214 hybridization. KP LAD 10 weeks after adeno-cre infection expressed substantial expressed IHH mRNA in malignant cells whereas only one of the six wild type samples 240 expressed IHH mRNA ( Fig. 5a, Supplement Fig. 6 ). All of the IHH mRNA positive 241 tumors had a predominance of lepidic histology with mucinous features (Supplement 242 Fig. 6 ). Lepidic histology has been correlated with less aggressive biology. The The Hh signaling pathway has been implicated in the regulation of angiogenesis in 261 normal tissues (77, 78) and cancer (79, 80) through induction of angiogenic factors including VEGFs and ANG1, 2. Examination of CD31 expression, a marker of 263 endothelial cells, showed decreased blood vessel density in LAD tumors treated with 264 anti-SHH/IHH 5E1 antibody compared to IgG 1 treated tumors ( Fig. 6a, b ). As the effects 265 of stromal Hh pathway inhibition were seen with mice when treatment was initiated 2 266 weeks after adeno-cre infection (Fig. 3b, d-k ), we hypothesized that the inability of 267 growing tumors to generate new vessels would lead to early hypoxia and production of 268 reactive oxygen species (81, 82) , that in turn, would promote tumor proliferation and 269 growth (83-85). We developed 2 macros (ROI_Draw and Nuclear_Fraction_Calculator) 270 for ImageJ (86) showed significantly higher fraction of nuclei stained with H2AX than tumors from IgG 1 277 treated mice (Fig 6c, d ), suggesting increased DNA damage from reactive oxygen 278 species (ROS). To assess whether ROS from stromal Hh pathway inhibition induced 279 accelerated tumor growth, KP mice were treated with 5E1 and N-acetyl cysteine (NAC), 280 as a scavenger of ROS and precursor to the antioxidant, glutathione (GSH) (Fig. 6e ).
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Treatment with NAC and 5E1 prolonged surv 282 ival compared to 5E1 and vehicle control ( Fig. 6f ) whereas treatment with NAC and IgG 1 283 did not affect survival ( Fig. 6g ). Furthermore, the median survival of 5E1 with NAC 284 approximated that of IgG 1 with vehicle control (Supplement Fig. 7) . Interestingly, the rate of metastases did not decrease when mice were treated with 5E1 and NAC 286 compared to 5E1 and vehicle control ( Fig. 6h ). However, the tumor burden of mice 287 treated with 5E1 and NAC decreased substantially compared to mice treated with 5E1 288 and vehicle control 10 weeks after adeno-cre infection (Fig. 6i, j) and corresponded to 289 decreased ROS as measured by H2AX stained nuclei (Fig. 6k, l) . These data suggest 290 that IHH restrains tumor growth through support of angiogenesis with limiting ROS 291 production early in the tumorigenic process.
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Discussion 294 We have shown that mutant KRAS LAD secretes Hh ligands to activate stromal cells in 295 a paracrine manner (Fig. 1g ), that IHH (Fig. 3) , rather than SHH, is the dominant ligand 296 in early transformed lung airway cells and that it restrains tumor growth ( Fig. 3g-i , 4d-f), 297 grade ( Fig. 3j, k) and metastases ( Fig. 3d-f ). Inhibition of stromal Hh pathway activation 298 by IHH decreased angiogenesis (Fig. 6a, b ) and significantly increased ROS (Fig 6c, d) 299 leading to rapid tumor growth ( Fig. 6i , j) and shorter survival (Fig. 6f ).
301
In accordance with previous studies (36-40, 90), paracrine Hh activation of stroma, 302 particularly early in the tumorigenic process, suppresses lung tumor growth, formation 303 of aggressive histologies and metastases. A surprising result of our studies was the 304 central role of IHH, instead of SHH, to suppress tumor growth. SHH is the dominant 305 ligand that regulates lung development (51-54, 91), adult lung airway homeostasis (55, 306 56, 92), and lung cancers (42, 43, 46, 50, 57) . IHH is expressed in the adult colon (93) 307 and prostate (90) and restrains the growth of colon (40, 94) and prostate (41) In our studies, loss of stromal pathway activation in KP LAD decreased blood vessel 313 density (Fig. 6a, b) suggesting that the Hh signaling pathway induces angiogenesis in 314 the lungs consistent with reports in other organs (77, 78, 95) . However, loss of stromal 
